It is complicated and I always expected some post hoc analysis of the individual patients. What I didn't expect was the dramatic improvement in the placebo patients at 26 weeks. I don't think I'm alone in that.
With a 52 week study, even if at at the end any improvement in the treatment groups had plateaued, you would think the extra time would have diminished any placebo effect.
Perhaps a question for the AGM would be when will they update us with the 52 week data.
research v. Phase II exam, page-3
Add 1AI (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.6¢ |
Change
0.000(0.00%) |
Mkt cap ! $10.12M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 25 | 6175844 | 0.6¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.7¢ | 279533 | 2 |
View Market Depth
| Last trade - 16.12pm 08/10/2024 (20 minute delay) ? |
| 1AI (ASX) Chart |
Day chart unavailable